Adam Bellack is an industry-focused transactional lawyer in Goodwin’s Life Sciences group. He handles licensing, collaboration and other strategic and commercial transactions for clients engaged in all aspects of the healthcare industry. Mr. Bellack represents a wide range of clients from startups and early stage pharma, biotech and medical device companies, to established Big Pharma companies and global manufacturers. Mr. Bellack has also represented founders, venture funds, universities, and tech companies entering the healthcare space. Mr. Bellack has worked on large transformative transactions and on transactions involving exciting new technologies at the forefront of medical innovation, including novel immunotherapies, antibody-drug conjugates (ADCs) and gene therapies. His experience representing industry participants on “all sides” of these transactions provides unique perspective and helps him identify practical solutions to difficult problems when structuring and negotiating complex arrangements for life sciences companies.
Areas of Practice
Domaines D’Expertise





Mr. Bellack advises clients on a broad range of transactional matters, including licensing, collaborations, product options and divestitures, affiliations, joint ventures, and other strategic transactions, commercial arrangements such as manufacturing, supply, distribution, promotion and development agreements, and research arrangements such as sponsored research and clinical trial agreements.

Mr. Bellack’s experience includes representing:

  • Gilead Sciences and Kite Pharma in parallel collaboration and license agreements with oNKo-innate to support discovery and development of next-generation drug and engineered cell therapies using natural killer (NK) cells*
  • Seattle Genetics in connection with co-development and co-commercialization agreements, including its co-commercialization agreement with Astellas for PADCEV™ (enfortumab vedotin-ejfv)*
  • BeneVir Biopharm, Pansend Life Sciences and HC2 Holdings in the sale of BeneVir and its oncolytic virus platform to Janssen Biotech, a subsidiary of Johnson & Johnson, for up to $1.04 billion in upfront and milestone payments*
  • Novartis in connection with:
    • restructuring transactions and product divestitures including (i) the out-license of its selective PI3K-delta inhibitor, leniolisib, to Pharming Group, and (ii) the sale of Korean rights to Famvir (famciclovir) to Ildong Pharmaceuticals*
    • its landmark portfolio transformation transactions with GlaxoSmithKline and Eli Lilly valued at more than $23 billion*
  • Sanofi in its $2.2 billion global collaboration with Regeneron to develop new antibody-based immuno-oncology products*
  • NextCure in connection with its formation, $67 million Series A financing and license and research agreements with Yale University*
  • TESARO in connection with its formation, equity financings, licensing transactions, and commercial agreements, including its license and collaboration agreement with Janssen Biotech involving Niraparib for the treatment of prostate cancer*
  • Precigen in connection with exclusive channel collaboration agreements, joint ventures, and the restructuring of its biofuels business*
  • A global technology company in licensing its glucose monitoring "smart lens" technology, and in the creation of a JV to develop next generation surgical robots*
*Denotes experience prior to joining Goodwin.
Professional Experience
Prior to joining Goodwin, Mr. Bellack was most recently a partner at Hogan Lovells US LLP in Washington, D.C, where he served as Co-Head (Americas) of the Life Sciences Transactions team.


Mr. Bellack was a 2021 recommended lawyer for Healthcare: life sciences  by The Legal 500 2021. Mr. Bellack has been consistently recognized as a “Rising Star” by Law360 and as one of the nation’s top young Life Sciences lawyers. He has also been ranked by Super Lawyers for his work in mergers & acquisitions, health care, technology transactions and business/corporate matters.

In The News









J.D., 2002
The University of Chicago Law School
A.B., 1999
Harvard University
magna cum laude


2002-2003 Alaska Supreme Court, Robert L. Eastaugh



District of Columbia
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique